No Data
No Data
No Data
No Data
No Data
Fate Therapeutics Currently Down 11 Consecutive Days, on Track for Record Losing Streak -- Data Talk
Fate Therapeutics, Inc. (FATE) is currently at $4.36, down $0.18 or 3.96% --Would be lowest close since Jan. 18, 2024, when it closed at $4.33 --Currently down 14 of the past 15 days --Currently do
Dow JonesApr 24 11:13 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
TipRanksApr 24 04:50 ET
Fate Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since December 2022 -- Data Talk
Fate Therapeutics, Inc. (FATE) is currently at $4.58, down $0.21 or 4.29% --Would be lowest close since Jan. 26, 2024, when it closed at $4.56 --Currently down 13 of the past 14 days --Currently do
Dow JonesApr 23 14:09 ET
Express News | Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target
Moomoo 24/7Apr 23 13:12 ET
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B Cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE) today announced that two presentations will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
GlobeNewswireApr 22 16:30 ET
Why Investors Shouldn't Be Surprised By Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Share Price Plunge
Fate Therapeutics, Inc. (NASDAQ:FATE) shares have retraced a considerable 28% in the last month, reversing a fair amount of their solid recent performance. The drop over the last 30 days has capped
Simply Wall StApr 19 06:37 ET
No Data
No Data